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VIROLOGY 132,261-270 (1934) 
Murine Hepatitis Virus-4 (Strain JHM)-Induced Neurologic Disease Is 
Modulated in Viva by Monoclonal Antibody 
MICHAEL J. BUCHMEIER,’ HANNA A. LEWICKI, PIERRE J. TALBOT, AND 
ROBERT L. KNOBLER 
Lkpartmmt of Immunology Scripps Clinic and Research Foundation, Lu Jolla, Califonzia 9.3’057 
Received May,%?@ 198~;accepted October22, 1983 
Monoclonal hybridoma antibodies directed against the polypeptides of murine hepatitis 
virus-4 (JHM strain) were tested for their ability to alter the course of a normally lethal 
intracerebral virus challenge. Three monoclonal antibodies directed against two distinct 
epitopes on the E2 glycoprotein of MHV-4 protected mice against lethal virus challenge 
and converted the infection from fatal encephalomyelitis to demyelination. A single neu- 
tralizing antihody directed against a third epitope on E2 as well as seven nonneutralizing 
antibodies to EZ, El, and N polypeptides did not protect against challenge. In mice which 
received protective antibody, MHV-4 infection was not blocked, however, virus grew to 
lower titers in liver and brain, and virus replication in the CNS was more restricted than 
in unprotected mice. Decreased involvement of neurons in the brains of protected mice 
was observed, and no evidence of neuronal infection in the spinal cords was found. In 
contrast, oligodendrocytes were infected in the presence of protective antibody, and evidence 
of demylination associated with mononuclear cell infiltration was found. These studies 
demonstrate that antibody to a single epitope on a viral glycoprotein can substantially 
alter the course and phenotype of disease. 
INTRODUCTION 
Murine hepatitis virus-4 (MHV-4) strain 
JHM is a neurotropic member of the co- 
ronaviridae. Infection by MHV-4 in the 
mouse is associated with encephalitis and 
demyelination (Bailey et al, 1949; Waks- 
man and Adams, 1962; Weiner, 1973). Fatal 
encephalitis associated with significant loss 
of neurons is the normal outcome of in- 
tracerebral inoculation, with resistance of 
mice to fatal disease apparently being con- 
trolled by a single autosomal recessive gene 
(Knobler et al, 1981a) expressed at the level 
of the neuron and macrophage. Recovery 
from the acute encephalitis is rare, and the 
infrequent survivors exhibit demyelination 
(Lampert et d, 1973; Weiner, 1973). Haspel 
and co-workers (1978) demonstrated that 
i To whom correspondence and requests for reprints 
should be addressed at Department of Immunology 
(IMM 15), Scripps Clinic and Research Foundation, 
10666 North Torrey Pines Road, La Jolla, Calif. 93937. 
a temperature sensitive mutant of MHV- 
4, designated ts 8, produced demyelination 
in over 90% of infected mice while pro- 
ducing encephalitis in less than 5%. The 
ts 8 mutant infects oligodendrocytes lead- 
ing to cell death, degeneration, and removal 
of their myelin sheaths by macrophages 
(Knobler et d, 1982). 
Mouse hepatitis viruses contain at least 
three major classes of structural proteins 
including the 50,000-Da nucleocapsid pro- 
tein (N), and two glycoproteins El and E2 
(Wege et aZ., 1979; Sturman et aL, 1980; 
Holmes et al, 1981). El is integrally as- 
sociated with the membrane in both a non- 
glycosylated Z&000-Da form and an O-gly- 
cosylated 25,000-Da form. E2 consists of 
two approximately 95,000-Da subunits 
which form a 180,000-Da dimer constitut- 
ing the large “petal” (peplomer) on the vi- 
rion envelope (Sturman et al, 1980). In our 
laboratory we have raised a library of hy- 
bridoma antibodies to these viral proteins 
to study the biology and biochemistry of 
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MHV and to probe the in vivo events in VimLs neutralization. Virus neutralizing 
disease. With these antibodies we were capacity of ascites fluids containing mono- 
able, in our initial studies, to assign the clonal antibody was quantitated by a 
viral components responsible for attach- plaque reduction neutralization assay. As- 
ment and cell-cell fusion to the E2 gly- cites fluids were diluted in MEM as indi- 
coprotein (Collins et ak, 1982), and to map cated and mixed with an equal volume (0.5 
the epitopic regions of these molecules ml) of virus dilution containing 120 to 200 
(Talbot et aL, 1984). In this report we have PFU of MHV-4. The virus-antibody mix- 
studied the ability of antibodies to specific tures were incubated at 37” for 30 min, 
viral proteins to alter the course of disease divided in half, and plated in duplicate on 
in vivo, and have mapped the property of monolayers of L-24 cells in 60-mm culture 
passive protection against lethal enceph- dishes. After adsorption for 1 hr, overlay 
alitis to specific epitopes on the E2 gly- medium was added and the plates were 
coprotein. further incubated 72 hr in a 37” COz in- 
cubator. Cells were fixed by the addition 
of 2 ml of 25% formalin in PBS for 4-18 
MATERIALS AND METHODS hr. Agar overlays were removed and 
monolayers stained with 0.1% crystal vi- 
Virus and cell culture. MHV-4 (JHM olet. Neutralization was expressed as the 
strain) was originally obtained from Dr. reciprocal of the antibody dilution giving 
Leslie Weiner and is routinely propagated 50% reduction in plaque number compared 
on L-24 cells as previously described (Has- with virus incubated in parallel with cul- 
pel et al, 1978; Collins et al., 1982). The ts ture medium not containing antibody. As- 
8 mutant MHV-4, which produces a high cites fluids directed against nonneutral- 
frequency of demyelinating disease with- izing antigens of MHV-4 (nucleocapsid 
out encephalitis, was isolated by Haspel et protein) or against other unrelated viruses 
c& (1978). Virus was enumerated by plaque often exhibited low levels of an MHV-4 
assay on L-24 cells. neutralizing activity (~300 PRD,/ml); 
Hybridwmu cells. Hybridoma cells pro- thus a control sample consisting of nu- 
ducing monoclonal antibodies to MHV-4 cleocapsid antibody was included in all as- 
were generated and characterized in this says. 
laboratory as previously described (Collins Passive antibody protection and assess- 
et &, 1982). All lines were cloned by lim- ment of demyelination BALB/c St mice 
iting dilution in 96-well plates at a ratio aged 4-6 weeks are exquisitely sensitive to 
of 0.1 cell per well. Specificity for viral intracerebral (ic) infection with MHV-4 
polypeptides and epitopes was established (Knobler et al, 1981a), and develop a rap- 
as described elsewhere (Collins et al, 1982; idly fatal encephalitis due to infection of 
Talbot et al, 1984). neurons. We have used such ic infected 
Ascites fluids were produced in BALB/ mice as a test system to assess the pro- 
c St mice. Briefly, mice were pretreated by tective effect of passively administered 
ip injection with 1 ml of Pristane (2, monoclonal antibodies on MHV-4 infection. 
6,10,14-tetramethylpentadecane, Aldrich Two protocols of antibody administration 
Chemical Co., Milwaukee, Wise.). Seven 
days later, 5 X lo6 to 1 X 10’ hybridoma 
were employed. In initial experiments, we 
gave mice daily doses of 25 ~1 of undiluted 
cells were injected intraperitoneally. As- ascites on Days -2, -1, 1,2,3, and 4 relative 
cites developed lo-14 days later, and were to virus challenge on Day 0. In order to 
harvested daily from unanesthetized mice minimize handling of mice after infection, 
by puncture with a 20-gauge needle. Ascites we subsequently adopted a protocol of a 
fluids were clarified by centrifugation at 
2500 g for 20 min, aliquoted, and stored at 
single dose of 200 ~1 of ascites on Day -1 
and found that this regimen was as efficient 
-20”. Immunoglobulin concentrations in as the first at conferring protection. In all 
ascites fluids were estimated by radial im- cases, virus challenge consisted of lo-50 
munodiffusion. PFU (approximately 30-150 LD& of wild- 
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type MHV-4 intracerebrally. This dose re- 
producibly yielded 100% mortality by 6 
days after infection. 
To assess demyelination in passively 
protected mice, we allowed survivors to live 
for 14-21 days after virus challenge, then 
sacrificed and perfused them via the left 
ventricle with glutaraldehyde-paraform- 
aldehyde fixative in PBS as previously de- 
scribed (Knobler et al. (1981b). Following 
perfusion, spinal cords and brains were 
dissected out and l-pm Epon sections were 
prepared and stained for myelin with-p 
phenylenediamine. Surveys for demyelin- 
ating foci routinely included examination 
of two sections each from cervical and 
lumbar spinal cord and one section of tho- 
racic cord. An animal was judged demye- 
linated if foci of axonal demyelination were 
observed in the white matter of any of 
these five sections. Immunoperoxidase 
staining for viral antigen was performed 
on 30-pm vibratome sections as previously 
described (Knobler et aL, 1981b) using pro- 
tein A peroxidase and monospecific rabbit 
antibody to MHV-4 (kindly supplied by 
K. V. Holmes, USPHS, Bethesda, Md.). For 
antigen studies, glutaraldehyde was omit- 
ted from the perfusion fixative. 
For virus titration, 10% homogenates of 
specified tissues were prepared from mice 
infected and treated as indicated and as- 
sayed on monolayers of L-24 cells. Virus 
titers were expressed as PFU per gram of 
tissue. 
RESULTS 
Neutralization bg mcmoclonal antibodies. 
Previous work from our laboratory estab- 
lished that MAb to the MHV-4 glycoprotein 
E2 neutralized virus in vitro (Collins et d, 
1982). We have extended these findings in 
surveying a larger panel of antibodies to 
the El and E2 glycoproteins using a more 
sensitive plaque reduction assay in which 
we determined PRD, titers for the mono- 
clonal ascites preparations used in the 
present studies. Titers observed ranged 
from approximately 8000 PRD,/ml to 
greater than 158,000 PRD,/ml for various 
ascites preparations as summarized in Ta- 
ble 1. Note that a low background titer 
generally less than 300 PRDdml was ob- 
served in preparations of nucleocapsid 
specific antibody as well as in unrelated 
monoclonal ascites and in some normal 
mouse sera (data not shown). Whether this 
TABLE 1 
VIRUS NEUTRALIZATION AND PASSIVE PROTECTION BY MONOCLONAL ANTIBODIES TO MHV-4 (JHM-STRAIN) 
Antibody Ig subclass 
5B19.2 IgGl 
5B170.3 IgGl 
5813.5 IgG2A 
4B11.6 IgG2A 
5B93.9 I& 
5B21.5 IgGl 
5B207.7 IgG2B 
5B216.8 IgG2A 
5A5.2 IgG3 
5B119.4 IgG2A 
5B11.5 IgG2A 
4B6.2 IgGl 
5B175.6 IgG2A 
None - 
Polypeptide 
specificity 
E2 
El 
N 
Neutralization 
(PRDdml) 
31600 
7950 
158,500 
31,600 
500 
250 
<lOO 
<lOO 
316 
400 
<lOO 
300 
tlO0 
- 
Passive protection” 
(survivors/total) 
34145 (76%) 
516 (83%) 
6/6 (100%) 
O/20 
O/6 
o/4 
o/5 
o/5 
3128 (11%) 
o/4 
NDb 
l/27 (4%) 
ND 
O/33 
D Passive protection against lethal intracerebral challenge with MHV-4. 
b ND, not data available. 
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naturally occurring activity represents 
specific antibody or a cross-reacting nat- 
ural antibody is under investigation. 
Passively transferred MAb blocks lethal 
encephalitis induced by MHV-4 Intrace- 
rebrally inoculated BALB/c mice are ex- 
quisitely sensitive to MHV-4. Infection of 
neurons of the CNS results in rapidly lethal 
encephalitis usually within 6 days. We 
tested two passive transfer regimens as 
described under Materials and Methods to 
attempt to alter the course of this normally 
lethal encephalitis. Both regimens were ef- 
fective, and the simpler single antibody 
dose protocol was adopted. Figure 1 shows 
the results of one such protection experi- 
ment in which we tested five different MAb 
to the MHV-4 E2 glycoprotein (5B19.2, 
5A13.5,5B170.3,4B11.6, and 5B93.9) and as 
a control, a single antibody to the N protein 
(4B6.2). Groups of six mice were given 200 
~1 of the indicated ascites on Day-l then 
challenged intracerebrally with 20 PFU of 
MHV-4 on Day 0. Survivors were observed 
daily for 21 days then sacrificed in order 
to score demyelinating lesions in the spinal 
cord. Note that mice receiving nonprotec- 
tive antibody (clones 4B11.6, 5B93.9, and 
- I 3 5 7 9 11 13 15 17 19 21 
Days Alter Vtruo Challenge 
FIG. 1. Passive protection of mice against lethal 
MHV-4 challenge by monoclonal antibody. Groups of 
six mice were given 206 ~1 of ascites fluids containing 
the antibodies indicated then challenged 1 day later 
with MI-IV-4 intracerebrally. Survival was scored over 
a 21-day interval. Note that three antibodies to the 
E2 glycoprotein (5B19.2, 5A13.5, and 5Bli’O-3) pro- 
tected against challenge while two other anti-E-2 an- 
tibodies 4B11.6 and 5B93.9 as well as the nucleocapsid 
antibody 4B6.2 did not protect. 
4B6.2) as well as mice not receiving MAb 
(data not shown) all died by Day 6 after 
infection. We have screened a panel of eight 
anti-E2, three anti-El, and one anti-N MAb 
and the results of these passive protection 
analyses are summarized with the neu- 
tralization data in Table 1. Note that MAb 
4B11.6 neutralized virus efficiently in vitro 
but showed no passive protection of mice 
against lethal challenge in viva. None of 
four nonneutralizing MAb to E2 gave sig- 
nificant protection in vivo. 
Timing and dose dependence of passive 
protecticm, The effect of antibody given 
passively prior to infection might be argued 
to be simply an in vivo neutralization 
whereby incoming virus in the challenge 
inoculum is prevented from infecting tar- 
gets in the CNS. To test this possibility, 
we altered the time of antibody transfer 
relative to challenge. Groups of six mice 
each were given a single 200-~1 dose of MAb 
5B19.2 on Days -1, 0, +l, and +2 relative 
to virus challenge on Day 0. Mortality was 
again scored over a 21-day interval. As ev- 
ident in Fig. 2, groups of six mice each 
receiving no antibody or MAb 4B6.2 on Day 
-1 all died by 6 days after infection as 
previously observed. In contrast, mice re- 
ceiving antibody on Days -1, 0, and +l 
showed 100, 100, and 83% survival, re- 
spectively, while 33% of those receiving 
antibody 2 days after infection survived 
for 21 days. Thus, the effect of passively 
transferred antibody is therapeutic and 
confers protection even if given after the 
establishment of CNS infection. 
To examine the quantity of antibody re- 
quired to protect against lethal challenge, 
we gave groups of six mice increasing doses 
of 5B19.2 ascites 1 day prior to ic challenge 
with MHV-4 then scored mortality as in- 
dicated above. Table 2 summarizes the re- 
sults of a typical experiment. A single dose 
of 25 ~1 of 5B19.2 ascites with a neutralizing 
titer of l:lO,OOO protected half of the chal- 
lenged mice. This dose of ascites in a 25 g 
mouse is approximately equivalent to a l/ 
1000 dilution (1 bl/g). 
Eflect of passively transferred antibody 
on virus growth in tissues. The observation 
that MAb was protective even if given after 
challenge suggested that the sparing effect 
MODULATION OF MHV-I-INDUCED DISEASE BY ANTIBODY 
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0 “‘3, 11”‘11’11’11” 
1 3 5 7 9 11 13 15 17 19 21 
Days After Vws Challenge 
FIG. 2. Effect of time of passive antibody admin- 
istration on survival following MHV-4 challenge. 
Groups of six mice each were given 200 pl of ascites 
fluid containing monoclonal antibody 5B19.2 on the 
days indicated and challenged with MHV-4 on Day 
0 and survival was scored. Note that antibody given 
on Days -1 (d-l), 0 (do), and +l (d+l) was highly 
efficient in protecting against lethal challenge and 
antibody given on day +2, (d+2) protected one-third 
of the challenged mice. Mice given nucleocapsid an- 
tibody 4B6.2 or no antibody on Day -1 died by Day 
6 after challenge. 
operated by blocking or slowing the spread 
of virus infection. To investigate this, we 
titered MHV infectivity in tissues follow- 
ing infection in the presence and absence 
of protective antibody. Brains and livers 
were titered to assess the effect of antibody 
on replication in CNS and peripheral tis- 
sues, respectively. MAb was passively 
transferred 1 day before ic challenge as 
TABLE 2 
MINIMUM PROTECTIVE DOSE OF 5B19.2 ASCITES” 
Survival 
at 21 days 
Volume of passively 
Group transferred ascites Survivors/ 
(n = 6) d-1 (~1) inoculated % 
I 200 6/6 100 
II 100 6/6 100 
III 50 3/5 60 
IV 25 316 50 
V 0 O/6 0 
a PRDSO, titer of 5B19.2 ascites determined by neu- Passively transferred MAb blocks itiec- 
tralization assay was l/10,000. tion. of new-m but not oligodmdmcytes. The 
TABLE 3 
VIRUS TITERS 4 DAYS AFTER INFECTION IN BRAINS 
AND LIVERS OF MICE RECEIVING PASSIVE ANTIBODY 
5B19.2 PRIOR TO CHALLENGE 
PFU/g” 
Group Passive antibody 
(n = 4) d-l Liver Brain 
I 
II 
III 
IV 
None 2.4 X ld 2.5 X 106 
545.2 ND” 5.4 x lo5 
4B11.6 2.0 x lo4 7.3 x lo6 
5B19.2 <2 x 16 1.3 x 10’ 
’ Mean of four mice per group. 
*ND, no data available. 
above and tissues were removed for titra- 
tion 4 days after infection, at a time when 
sufficient unprotected mice remained alive 
for study. Table 3 summarizes these re- 
sults. We noted that titers in the brains 
of mice receiving MAb 5B19.2 were reduced 
by a factor of 20 relative to untreated con- 
trols. This reduction was not observed in 
mice receiving nonprotective antibody to 
El (5A5.2) or E2 (4B11.6). In the protected 
mice (group IV, Table 3), we were unable 
to detect virus in the livers at a threshold 
value of 200 PFU per gram whereas control 
mice (groups I and III) had greater than 
2 X lo4 PFU per gram in their livers on 
Day 4. To confirm that this difference re- 
flected actual reduction in virus replication 
and not merely a damping effect due to 
high concentration of MAb in the liver ho- 
mogenates, we examined H and E sections 
as well as fluorescein-stained cryostat sec- 
tions of livers from protected and unpro- 
tected mice. Mice which received no pro- 
tective MAb showed numerous large ne- 
crotic foci of hepatocytes (Fig. 3A), stained 
for MHV-4 antigens (Fig. 3B), but only 
limited isolated foci of infected cells were 
observed in sections of livers from mice 
receiving protective MAb 5B19.2 (Figs. 3C, 
D). Taken together, these findings indicate 
that virus replication is substantially de- 
creased by passively administered MAb 
both in the CNS and peripheral compart- 
ments. 
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FIG. 3. Hepatic lesions in unprotected (A, B) and antibody-protected (C, D) mice, following 
intracerebral challenge with 20 PFU of MHV-4. Antigens were stained using a rabbit antibody to 
MHV which recognizes all of the viral polypeptides. (A) One of multiple necrotic foci with infiltrating 
polymorphonuclear leukocytes, in an unprotected mouse. 250X, H & E. (B) Fluorescein-labeled 
MHV antigens in an MHV-l-induced hepatic lesion in an unprotected mouse. 250X. (C) An isolated 
focus of necrotic hepatocytes in a 5B19.2-protected mouse. 250X, H & E. (D) Fluorescein-labeled 
MHV antigens in an isolated MHV-l-induced hepatic lesion in a 5B19.2-protected mouse. 250X, 
H & E. 
observation of lower virus titers in the 
brains of protected mice suggested that vi- 
rus replication was restricted to fewer cells 
in these animals. To test this, we compared 
the distribution of MHV antigens in sec- 
tions of spinal cord among infected and 
untreated, infected and unprotected, and 
infected and protected mice. Figure 4 dem- 
onstrates peroxidase-labeled MHV anti- 
gens in a section from an MHV-l-infected 
untreated mouse. There are MHV antigens 
in neuronal cells in the gray matter (Fig. 
4A) as well as in oligodendrocytes with 
their processes surrounding multiple my- 
elin sheaths in the white matter (Fig. 4B). 
The MHV-4 antigen distribution in in- 
fected animals given nonprotective anti- 
body is virtually identical. In contrast, mice 
infected with MHV-4 and protected by an- 
tibody have a different distribution of 
MHV antigens. Figure 5 demonstrates 
peroxidase-labeled MHV antigen in oli- 
godendrocytes, identified by their cyto- 
plasmic processes surrounding multiple 
myelin sheaths (Knobler et uL, 1981b, 1982), 
in the white matter. Neurons containing 
MHV antigen were not usually found in 
the spinal cord of antibody-protected mice. 
These findings were corroborated by 
histopathology. Both MHV-kinfected, un- 
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FIG. 4. Antigen localization in the spinal cord of an untreated animal following intracerebral 
challenge with 20 PFU of MHV-4. Antigens were stained with rabbit antiserum to MHV. (A) 
Protein-A peroxidase-labeled MHV antigens in an anterior horn neuronal cell of the lumbar spinal 
cord. 499X. (B) Protein-A peroxidase-labeled MHV antigens in oligodendrocytes in the white matter 
of the lumbar spinal cord. 259X. The cells are recognized as oligodendrocytes by their multiple 
processes surrounding the central myelin sheaths. 
treated mice and MHV-4-infected mice 
treated with nonprotective MAb had his- 
topathological evidence of necrotizing en- 
cephalomyelitis with neuronophagia. They 
showed evidence of white matter involve- 
ment as well, but did not survive long 
enough to allow the demonstration of de- 
FIG. 5. Antigen localization in the spinal cord of a 
5B19.2 antibody-treated animal following intracere- 
bra1 challenge with 26 PFU of MHV-4. MHV antigen 
in oligodendrocytes, characterized by processes sur- 
rounding multiple myelin sheaths, in the white matter 
of lumbar spinal cord were identified using rabbit 
antiserum to MHV followed by protein A peroxidase. 
210X. The inset demonstrates labeled viral antigens 
on both external and internal surfaces (arrowheads) 
of a myelin sheath, characteristic of the distribution 
of oligodendrocyte cytoplasm. 569X. 
myelination. Neurons of mice infected with 
MHV-4 and protected by antibody were 
spared, but these animals did have definite 
areas of demyelination (Fig. 6A). These 
demyelinated foci were frequently asso- 
ciated with perivascular infiltration by 
mononuclear cells (Fig. 6B). 
Demonstration of demyelination in the 
presence of MHV-4 protective antibody 
suggested that the effects of antibody were 
different on neurons and oligodendrocytes. 
Since the ts 8 mutant of MHV-4 causes 
infection of oligodendrocytes, we evaluated 
the effect of protective antibody on the de- 
myelinating disease induced by ts 8 virus. 
Two groups of seven mice each received 
either protective MAb 5B19.2 or no anti- 
body, and both groups were challenged 1 
day later with 10,000 PFU of ts 8 virus ic. 
Demyelination was found in 100% of the 
mice examined from each group suggesting 
that MAb 5B19.2 can protect neuronal cells 
from histopathologic disease, but does not 
similarly protect oligodendrocytes. 
DISCUSSION 
Factors which influence pathogenesis of 
virus infections are complex and may be 
determined at the level of virus or host. 
In the case of MHV-4 infection, previous 
studies have established that an attenuated 
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FIG. 6. Demyelination of the lumbar spinal cord of 5B19.2 antibody-treated animals following 
intracerebral challenge with 20 PFU of MHV-4. (A) Subpial demyelination is evident in this l-pm 
plastic embedded transverse section of spinal cord. 400X, pphenylenediamine. (B) Subpial de- 
myelination is evident in this l-pm plastic embedded longitudinal section of spinal cord. Demyelinated 
axons are present in the right side of this photomicrograph. Perivascular mononuclear cells are 
observed in this lesion. 400X, pphenylenediamine. 
ts mutant of MHV-JHM (Haspel et aL, 
19’78) virus showed decreased encephali- 
togenicity while retaining the ability to in- 
duce CNS demyelination. In the present 
study, we have investigated the influence 
on MHV-4 infection of passively trans- 
ferred antibodies to single epitopes on the 
viral glycoproteins. Our results demon- 
strate that specific monoclonal antibodies 
to the E2 glycoprotein block encephalitis 
and convert a normally lethal infection to 
nonfatal demyelinating disease. This spar- 
ing effect upon passive transfer is re- 
stricted to a subset of MAb which react 
with the A (E2) and B (E2) epitopes but 
is not a property of antibody to epitope C 
(E2) or of MAb to the MHV El or N poly- 
peptides (Talbot et aL, 1934). Further, al- 
though all of the protective antibodies ex- 
amined neutralized virus infectivity in vi- 
tro, one MAb (4B11.6) directed against 
epitope C (E2) neutralized virus efficiently 
in vitro but showed no sparing effect in 
viva, thus the properties of in vitro neu- 
tralization and in tivo protection can be 
distinguished and appear to map to distinct 
subsets of epitopes on E2. 
Protective antibody does not prevent in- 
fection of CNS cells by MHV. Further, rep- 
lication was decreased but not completely 
blocked by antibody. Virus titers in the 
brains of mice treated with protective doses 
of antibody prior to infection were ap- 
proximately 5% of those reached in control 
unprotected mice (Table 3). Antibody was 
found to be effective in conferring protec- 
tion when given as late as l-2 days after 
virus challenge (Fig. 2). Thus, the sparing 
effect is both therapeutic in that the titer 
of virus and severity of pathology are less- 
ened, and prophylactic because lethal en- 
cephalitis is prevented. It is unlikely that 
the absence of liver lesions in antibody- 
protected mice is a significant factor in 
their survival since much larger doses (1099 
PFU) of MHV-4 than used in these studies 
cause only subacute hepatitis when given 
intraperitoneally. 
The mechanism by which antibody-me- 
diated protection functions appear to be in 
blocking the spread of infection in neurons. 
It is apparent from the data in Table 3 that 
virus replicates in the brains of protected 
mice but to diminished levels relative to 
control mice. Only a few neurons bearing 
viral antigen could be demonstrated in 
these brains by immunofluorescence (data 
not shown). Further, no evidence of MHV 
replication was found in neurons in the 
spinal cord. The sparing effect of MAb was 
selective for neuronal cells. Infected oli- 
godendrocytes and resultant demyelination 
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were observed in spinal cords of infected 
and passively protected mice (Figs. 5, 6). 
Further, antibody which protected against 
lethal encephalitis did not block demye- 
lination induced by the ts 8 mutant of 
MHV-4. The observed restriction of virus 
replication in the neuronal cells but not 
oligodendrocytes suggests that infection 
spreads via different mechanisms in these 
two cell types. Whether this is due to dif- 
ferences in the mode of cell-to-cell spread 
or reflects distinct receptors for MHV-4 on 
each cell type is a matter for further study. 
In addition to the altered virus tropism in 
the presence of antibody, we found that 
the characteristics of the demyelinating 
lesions were changed. Lesions in antibody- 
protected mice showed increased cellular- 
ity with frequent perivascular cuffing in 
contrast to the lesions usually observed 
(Knobler et aL, 1982) following MHV-4 in- 
fection. 
This model system demonstrates that 
antibody response to precisely defined re- 
gions on a viral glycoprotein may induce 
profound changes in the pathogenesis of 
infection and the phenotype of disease. 
Conceptually, such factors may be of im- 
portance following primary infections, 
where an early response to a critical epi- 
tape(s) might influence the course of dis- 
ease. Stohlman and Weiner (1981) have 
shown that mice surviving acute MHV-4 
encephalomyelitis have neutralizing an- 
tibody in the circulation and develop 
chronic demyelination. Similarly, the rep- 
ertoire of response to a primary infection 
may influence the course of subsequent in- 
fection by a related virus. Human viral 
diseases such as subacute sclerosing pan- 
encephalitis (Vandvik, 1973) and progres- 
sive rubella panencephalitis (Wolinsky et 
al, 1976) occur in the presence of high titers 
of antibody to measles and rubella viruses, 
respectively. In the human demyelinating 
disease multiple sclerosis, there are ele- 
vated titers of antibodies to a number of 
common viruses such as measles, varicella, 
herpes, and others (Norrby, 19’78). Al- 
though causal relationships between the 
respective viruses, the presence of these 
antibodies, and demyelinating disease have 
not been established, the present model 
system provides new insight into the po- 
tential role of selected specific antibodies 
in leading to host survival from fatal in- 
fection, with development of a chronic dis- 
ease. Finally, this model offers the oppor- 
tunity to study the factors which govern 
the infection of and spread within specific 
populations of CNS cells by MHV-4 at the 
molecular level. 
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